Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,561 to 1,580 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer. | Front Cell Dev Biol | 2022 | 35223828 | PubTator, text mining | PubMed |
| Implications of Human Antimicrobial Peptide Defensin Beta-1 in Clinical Oral Squamous Cell Carcinoma Patients via an Integrated Bioinformatics Approach. | Comput Math Methods Med | 2022 | 35222682 | PubTator, text mining | PubMed |
| FAM46C as a Potential Marker for Pan-Cancer Prognosis and Predicting Immunotherapeutic Efficacy. | Front Genet | 2022 | 35222533 | PubTator, text mining | PubMed |
| Hypoxia-Inducible Factor-2 Alpha Regulates the Migration of Fibroblast-like Synoviocytes via Oxidative Stress-Induced CD70 Expression in Patients with Rheumatoid Arthritis. | Int J Mol Sci | 2022 | 35216458 | PubTator, text mining | PubMed |
| The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA. | Pharmaceutics | 2022 | 35214191 | PubTator, text mining | PubMed |
| Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. | Curr Treat Options Oncol | 2022 | 35212892 | PubTator, text mining | PubMed |
| Alternative splicing and alternative polyadenylation define tumor immune microenvironment and pharmacogenomic landscape in clear cell renal carcinoma. | Mol Ther Nucleic Acids | 2022 | 35211354 | PubTator, text mining | PubMed |
| Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. | Front Immunol | 2022 | 35211124 | PubTator, text mining | PubMed |
| Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma. | J Inflamm Res | 2022 | 35210814 | PubTator, text mining | PubMed |
| RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas. | Sci Rep | 2022 | 35210438 | PubTator, text mining | PubMed |
| Host Defenses to Viruses: Lessons from Inborn Errors of Immunity. | Medicina (Kaunas) | 2022 | 35208572 | PubTator, text mining | PubMed |
| Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. | Cancers (Basel) | 2022 | 35205725 | PubTator, text mining | PubMed |
| Circular RNAs Modulate Cancer Hallmark and Molecular Pathways to Support Cancer Progression and Metastasis. | Cancers (Basel) | 2022 | 35205610 | PubTator, text mining | PubMed |
| Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer. | Diagnostics (Basel) | 2022 | 35204342 | PubTator, text mining | PubMed |
| Immunotherapeutic Approaches for Glioblastoma Treatment. | Biomedicines | 2022 | 35203636 | PubTator, text mining | PubMed |
| The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle? | Biomedicines | 2022 | 35203609 | PubTator, text mining | PubMed |
| Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma. | Cancer Cell Int | 2022 | 35193632 | PubTator, text mining | PubMed |
| RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. | Mol Cancer | 2022 | 35189921 | PubTator, text mining | PubMed |
| The Histone H3K27me3 Demethylases KDM6A/B Resist Anoikis and Transcriptionally Regulate Stemness-Related Genes. | Front Cell Dev Biol | 2022 | 35186918 | PubTator, text mining | PubMed |
| The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. | Front Immunol | 2022 | 35185904 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=79